AlzChem Group AG Logo

AlzChem Group AG

ACT.DE

(4.0)
Stock Price

57,20 EUR

14.75% ROA

39.57% ROE

7.85x PER

Market Cap.

527.132.340,00 EUR

30.58% DER

2.32% Yield

8.18% NPM

AlzChem Group AG Stock Analysis

AlzChem Group AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

AlzChem Group AG Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (20.24%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Net Profit Growth

This company has consistently achieved strong net profit growth over the past five years, demonstrating a solid financial performance and making it an appealing investment option.

4 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

5 Dividend Growth

The company's dividend growth has exhibited a remarkable upward trend over the past five years, consistently delivering higher returns to investors.

6 ROA

The stock's ROA (7.2%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

7 PBV

The stock's PBV ratio (1.47x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

8 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

9 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

10 Dividend

Investors can take comfort in the fact that the company has consistently distributed dividends over the past three years, demonstrating a commitment to rewarding shareholders.

11 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (479) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

AlzChem Group AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

AlzChem Group AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

AlzChem Group AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

AlzChem Group AG Revenue
Year Revenue Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 287.384.000 100%
2013 301.763.000 4.76%
2014 298.358.000 -1.14%
2015 329.212.000 9.37%
2016 327.185.000 -0.62%
2017 353.920.000 7.55%
2018 375.217.000 5.68%
2019 376.072.000 0.23%
2020 379.257.000 0.84%
2021 422.293.000 10.19%
2022 542.223.000 22.12%
2023 483.296.000 -12.19%
2023 540.649.000 10.61%
2024 1.145.020.000 52.78%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

AlzChem Group AG Research and Development Expenses
Year Research and Development Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 7.986.000 100%
2015 8.601.000 7.15%
2016 8.658.000 0.66%
2017 9.015.000 3.96%
2018 8.678.000 -3.88%
2019 9.310.000 6.79%
2020 9.363.000 0.57%
2021 9.688.000 3.35%
2022 10.788.000 10.2%
2023 0 0%
2023 11.413.000 100%
2024 19.676.000 42%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

AlzChem Group AG General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 86.415.000 100%
2013 92.081.000 6.15%
2014 96.514.001 4.59%
2015 -1.013.139 9626.23%
2016 40.384.000 102.51%
2017 18.930.000 -113.33%
2018 17.791.000 -6.4%
2019 17.731.000 -0.34%
2020 17.084.000 -3.79%
2021 11.169.000 -52.96%
2022 11.354.000 1.63%
2023 0 0%
2023 12.731.000 100%
2024 15.916.000 20.01%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

AlzChem Group AG EBITDA
Year EBITDA Growth
2008 -5.133
2009 -5.308 3.32%
2010 -12.556 57.73%
2011 -5.120 -145.23%
2012 -3.747 -36.64%
2013 -4.428 15.36%
2014 -9.825 54.94%
2015 -30.862 68.17%
2016 -28.369 -8.79%
2017 46.179.000 100.06%
2018 55.576.000 16.91%
2019 50.342.000 -10.4%
2020 54.105.000 6.95%
2021 62.689.000 13.69%
2022 64.629.000 3%
2023 80.780.000 19.99%
2023 78.142.000 -3.38%
2024 196.324.000 60.2%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

AlzChem Group AG Gross Profit
Year Gross Profit Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 159.573.000 100%
2013 168.729.001 5.43%
2014 170.760.000 1.19%
2015 184.908.000 7.65%
2016 85.782.000 -115.56%
2017 223.976.000 61.7%
2018 232.169.000 3.53%
2019 237.279.000 2.15%
2020 250.581.000 5.31%
2021 268.338.000 6.62%
2022 282.724.000 5.09%
2023 289.704.000 2.41%
2023 136.547.000 -112.16%
2024 335.696.000 59.32%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

AlzChem Group AG Net Profit
Year Net Profit Growth
2008 -4.816
2009 -5.284 8.88%
2010 -10.949 51.74%
2011 -4.630 -136.53%
2012 -3.747 -23.54%
2013 -4.427 15.36%
2014 -8.044 44.96%
2015 -30.862 73.94%
2016 -28.752 -7.34%
2017 20.393.000 100.14%
2018 22.644.000 9.94%
2019 17.976.000 -25.97%
2020 19.694.000 8.72%
2021 27.593.000 28.63%
2022 30.052.000 8.18%
2023 34.452.000 12.77%
2023 34.621.000 0.49%
2024 106.316.000 67.44%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

AlzChem Group AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 2 100%
2018 2 0%
2019 2 -100%
2020 2 0%
2021 3 50%
2022 3 0%
2023 3 33.33%
2023 3 0%
2024 10 70%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

AlzChem Group AG Free Cashflow
Year Free Cashflow Growth
2012 2.630.000
2013 -2.335.000 212.63%
2014 -37.100.860 93.71%
2015 -19.863.186 -86.78%
2016 -18.580.075 -6.91%
2017 5.786.000 421.12%
2018 -5.473.000 205.72%
2019 2.249.000 343.35%
2020 19.878.000 88.69%
2021 14.481.000 -37.27%
2022 -33.308.000 143.48%
2023 4.890.000 781.15%
2023 52.114.000 90.62%
2024 51.390.000 -1.41%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

AlzChem Group AG Operating Cashflow
Year Operating Cashflow Growth
2012 20.712.000
2013 15.575.000 -32.98%
2014 140 -11124900%
2015 -49.186 100.28%
2016 -36.075 -36.34%
2017 30.664.000 100.12%
2018 34.655.000 11.52%
2019 43.631.000 20.57%
2020 48.710.000 10.43%
2021 43.016.000 -13.24%
2022 -4.240.000 1114.53%
2023 4.890.000 186.71%
2023 72.671.000 93.27%
2024 63.829.000 -13.85%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

AlzChem Group AG Capital Expenditure
Year Capital Expenditure Growth
2012 18.082.000
2013 17.910.000 -0.96%
2014 37.101.000 51.73%
2015 19.814.000 -87.25%
2016 18.544.000 -6.85%
2017 24.878.000 25.46%
2018 40.128.000 38%
2019 41.382.000 3.03%
2020 28.832.000 -43.53%
2021 28.535.000 -1.04%
2022 29.068.000 1.83%
2023 0 0%
2023 20.557.000 100%
2024 12.439.000 -65.26%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

AlzChem Group AG Equity
Year Equity Growth
2008 33.475
2009 28.191 -18.74%
2010 17.242 -63.5%
2011 12.612 -36.71%
2012 8.865 -42.27%
2013 51.938 82.93%
2014 -41.355.949 100.13%
2015 -41.293.949 -0.15%
2016 86.000 48116.22%
2017 57.894.000 99.85%
2018 68.391.000 15.35%
2019 61.350.000 -11.48%
2020 68.658.000 10.64%
2021 89.564.000 23.34%
2022 145.946.000 38.63%
2023 163.559.000 10.77%
2023 159.422.000 -2.59%
2024 182.552.000 12.67%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

AlzChem Group AG Assets
Year Assets Growth
2008 65.975
2009 65.691 -0.43%
2010 55.321 -18.75%
2011 17.412 -217.72%
2012 14.110 -23.4%
2013 13.660 -3.29%
2014 25.225 45.85%
2015 36.846 31.54%
2016 64.389 42.78%
2017 280.181.000 99.98%
2018 313.551.000 10.64%
2019 342.583.000 8.47%
2020 354.296.000 3.31%
2021 377.667.000 6.19%
2022 422.860.000 10.69%
2023 424.677.000 0.43%
2023 429.130.000 1.04%
2024 463.425.000 7.4%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

AlzChem Group AG Liabilities
Year Liabilities Growth
2008 32.500
2009 37.500 13.33%
2010 38.079 1.52%
2011 4.800 -693.31%
2012 5.245 8.48%
2013 11.722 55.26%
2014 25.225 53.53%
2015 36.846 31.54%
2016 64.389 42.78%
2017 222.287.000 99.97%
2018 245.160.000 9.33%
2019 281.233.000 12.83%
2020 285.638.000 1.54%
2021 288.103.000 0.86%
2022 276.914.000 -4.04%
2023 261.118.000 -6.05%
2023 267.688.000 2.45%
2024 280.873.000 4.69%

AlzChem Group AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
80.65
Net Income per Share
6.6
Price to Earning Ratio
7.85x
Price To Sales Ratio
0.64x
POCF Ratio
3.9
PFCF Ratio
5.08
Price to Book Ratio
2.92
EV to Sales
0.66
EV Over EBITDA
3.95
EV to Operating CashFlow
3.99
EV to FreeCashFlow
5.2
Earnings Yield
0.13
FreeCashFlow Yield
0.2
Market Cap
0,53 Bil.
Enterprise Value
0,54 Bil.
Graham Number
51.32
Graham NetNet
-12.03

Income Statement Metrics

Net Income per Share
6.6
Income Quality
2.01
ROE
0.4
Return On Assets
0.14
Return On Capital Employed
0.27
Net Income per EBT
0.72
EBT Per Ebit
0.97
Ebit per Revenue
0.12
Effective Tax Rate
0.28

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.39
Operating Profit Margin
0.12
Pretax Profit Margin
0.11
Net Profit Margin
0.08

Dividends

Dividend Yield
0.02
Dividend Yield %
2.32
Payout Ratio
0.18
Dividend Per Share
1.2

Operating Metrics

Operating Cashflow per Share
13.27
Free CashFlow per Share
10.19
Capex to Operating CashFlow
0.23
Capex to Revenue
0.04
Capex to Depreciation
0.8
Return on Invested Capital
0.3
Return on Tangible Assets
0.15
Days Sales Outstanding
34.65
Days Payables Outstanding
37.53
Days of Inventory on Hand
78.69
Receivables Turnover
10.53
Payables Turnover
9.73
Inventory Turnover
4.64
Capex per Share
3.08

Balance Sheet

Cash per Share
4,53
Book Value per Share
17,94
Tangible Book Value per Share
17.14
Shareholders Equity per Share
17.74
Interest Debt per Share
6.1
Debt to Equity
0.31
Debt to Assets
0.12
Net Debt to EBITDA
0.09
Current Ratio
2.33
Tangible Asset Value
0,17 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
337588000
Working Capital
0,15 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,08 Bil.
Average Payables
0,03 Bil.
Average Inventory
102655500
Debt to Market Cap
0.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

AlzChem Group AG Dividends
Year Dividends Growth
2020 1
2021 1 0%
2022 1 100%
2023 1 0%
2024 1 0%

AlzChem Group AG Profile

About AlzChem Group AG

AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand. It also provides fine and specialty chemicals, including products based on calcium carbide, calcium cyanamide, hydrogen cyanamide, dicyandiamide, guanidine, guanamines, and nitroguanidine, as well as aromatic and aliphatic nitriles; calcium cyanamide under the PERLKA name; germicide for use in pig pens under the ALZOGUR name; plant growth regulators under the Dormex and Sitofex name; and plant protection additives under the BREAK-THRU name. In addition, the company offers products for use in hot metal desulfurization and secondary metallurgy applications; and technical gases. Further, it provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.

CEO
Mr. Andreas Niedermaier
Employee
1.506
Address
Dr.-Albert-Frank-Strasse 32
Trostberg, 83308

AlzChem Group AG Executives & BODs

AlzChem Group AG Executives & BODs
# Name Age
1 Mr. Andreas Losle
Chief Financial Officer & Member of Management Board
70
2 Dr. Georg Weichselbaumer
Chief Sales Officer & Member of Executive Board
70
3 Mr. Klaus Dieter Englmaier
Member of Executive Board & Chief Operating Officer
70
4 Mr. Andreas Niedermaier
Chief Executive Officer & Chairman of Executive Board
70

AlzChem Group AG Competitors